A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole (CSC/Keto)

This study has been completed.
LuEsther T. Mertz Retinal Research Center
Information provided by (Responsible Party):
Joan, Manhattan Eye, Ear & Throat Hospital
ClinicalTrials.gov Identifier:
First received: September 13, 2005
Last updated: October 24, 2012
Last verified: October 2012
The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).

Condition Intervention Phase
Chronic Central Serous Chorioretinopathy
Drug: ketoconazole
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole.

Resource links provided by NLM:

Further study details as provided by Manhattan Eye, Ear & Throat Hospital:

Primary Outcome Measures:
  • Visual acuity (ETDRS) after 6 weeks of treatment [ Time Frame: 18 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Changes in the choroidal vascular pattern as observed on FA and changes at the posterior pole as measured with optical coherence tomography [ Time Frame: 18 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 5
Study Start Date: May 2005
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Drug: ketoconazole

Drug: ketoconazole

Other Names:


600mg. /day for 6 weeks

Drug: ketoconazole
600mg. /day for 6 weeks

Detailed Description:

A complete ophthalmic evaluation and tests: autofluorescence and Fluorescein angiography, Color Fundus Photography, OCT, including liver and adrenal functions and pregnancy test, if applicable will be done on the screening visit. If the patient is eligible, the patient will be started on ketoconazole 600 mg per day by mouth for the following next 6 weeks. The patient will be rechecked at weeks 5-6, 10,14 and 18. During all these visits a complete ophthalmic examination autofluorescence, OCT, and color fundus photographs will be done.

Repeat Liver and Adrenal function tests will be done at weeks 5-6 and 10 visits.

On the exit visit, all the ophthalmic tests and procedures on the baseline visit will be done. Adverse events, and concomitant medications and treatments will be reported on all visits.


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age less than 60 years
  2. Must have clinical signs of CSC with leakage from the level of the RPE during fluorescein angiography and neurosensory detachment documented by optical coherence tomography (OCT).
  3. Be able to return for all study visits for 3 months' duration.
  4. Be able to provide written informed consent
  5. Must have sufficiently clear media to allow for adequate fundus photography

Exclusion Criteria:

  1. Have choroidal neovascularization.
  2. Have any evidence of clinically significant intraocular inflammation, angioid streaks, presumed ocular histoplasmosis syndrome, or other precursor of choroidal neovascularization.
  3. Have additional eye disease that compromises the visual acuity of the study eye.
  4. Are receiving any systemic steroid therapy
  5. Have any significant medical history
  6. Have a history of severe hypersensitivity reaction to any of the dyes or the drug used in the study.
  7. Have any history of ocular conditions that may mimic CSC
  8. Are pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00211393

United States, New York
Manhattan Eye, Ear & Throat Hospital
New York, New York, United States, 10021
Sponsors and Collaborators
Manhattan Eye, Ear & Throat Hospital
LuEsther T. Mertz Retinal Research Center
Principal Investigator: K. Bailey Freund, MD Manhattan Eye, Ear & Throat Hospital
  More Information

Responsible Party: Joan, K. Bailey Freund, M.D., Manhattan Eye, Ear & Throat Hospital
ClinicalTrials.gov Identifier: NCT00211393     History of Changes
Other Study ID Numbers: M00.013 
Study First Received: September 13, 2005
Last Updated: October 24, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Eye Diseases
Retinal Diseases
14-alpha Demethylase Inhibitors
Anti-Infective Agents
Antifungal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on May 02, 2016